For Investors in Neurotherapeutics and Brain Health

Rigorous Science. Fewer Surprises.

Nine out of ten CNS programs fail. Most of those failures were predictable — and preventable — with the right scientific scrutiny before capital was committed.

SignalNeuro Partners brings what generalist evaluators can't: decades of hands-on translational neuroscience, from bench through biomarker validation to clinical readout. We find what standard due diligence misses — and we tell you plainly what it means for your investment.

Decision-grade scientific due diligence for neurotherapeutics and brain health

Scientific Validity Methodology Data quality, endpoint selection, and whether findings will hold under independent scrutiny

Technology Feasibility Whether the science can realistically achieve claimed outcomes given known translational barriers

Clinical Trial Risk Placebo response rates, patient stratification, and trial design robustness against real-world failure models

Competitive Landscape Failed predecessor programs, true differentiation, and what the field has already tested

Translational Risk Target validation strength, biomarker strategy, species-to-human translation assumptions, and where the program is most likely to break before it reaches the clinic

Investment Recommendation Evidence-based guidance on investment viability, deal-breaker identification, and scoring delivered with an explicit go, no-go, or conditional recommendatio

Deliverables

Comprehensive written report, executive summary, and presentation deck — ready for your investment committee. Delivered in 2–4 weeks.

What We Do